Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fruquintinib + PD-1 inhibitor (Ruijin Hospital)
- Development stage
- Unknown
- Lead developer
- HUTCHMED
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Fruquintinib + PD-1 inhibitor is a combination therapy being evaluated as a first-line maintenance treatment for patients with HER2-negative advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Fruquintinib is a highly selective and potent oral small molecule inhibitor of VEGFR-1, -2, and -3, which blocks tumor-induced angiogenesis. The PD-1 inhibitor component (which may include nivolumab, sintilimab, tislelizumab, or pembrolizumab) is a monoclonal antibody that targets the programmed cell death protein 1 receptor on T-cells, preventing its interaction with ligands PD-L1 and PD-L2 to restore anti-tumor immune responses. This regimen is typically administered after patients achieve disease control with initial platinum-based chemotherapy.
- Other names
- fruquintinib plus PD-1 monoclonal antibodyfruquintinib + PD-1 inhibitor
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on fruquintinib + PD-1 inhibitor (Ruijin Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fruquintinib + PD-1 inhibitor (Ruijin Hospital).